Aclaris Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M |
| Cost of revenue | $2.1M | $2.8M | $3.4M | $4.0M | $4.7M |
| Cash from operations | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M |
| Capital expenditure | $111,000 | $121,000 | $1.3M | $605,000 | $308,000 |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M |
| Impairments | — | — | $6.6M | — | — |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M |
Shares outstanding 139.7M · Free float 81.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.